JP2006508665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508665A5 JP2006508665A5 JP2004557611A JP2004557611A JP2006508665A5 JP 2006508665 A5 JP2006508665 A5 JP 2006508665A5 JP 2004557611 A JP2004557611 A JP 2004557611A JP 2004557611 A JP2004557611 A JP 2004557611A JP 2006508665 A5 JP2006508665 A5 JP 2006508665A5
- Authority
- JP
- Japan
- Prior art keywords
- butyrylcholinesterase
- butyrylcholinesterase variant
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010053652 Butyrylcholinesterase Proteins 0.000 claims description 14
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 102000021944 Butyrylcholinesterase Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 102100032404 Cholinesterase Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108010091086 Recombinases Proteins 0.000 description 6
- 102000018120 Recombinases Human genes 0.000 description 6
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31066602A | 2002-12-04 | 2002-12-04 | |
| PCT/US2003/038684 WO2004050041A2 (en) | 2002-12-04 | 2003-12-04 | Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508665A JP2006508665A (ja) | 2006-03-16 |
| JP2006508665A5 true JP2006508665A5 (enExample) | 2007-02-01 |
Family
ID=32468084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004557611A Pending JP2006508665A (ja) | 2002-12-04 | 2003-12-04 | 化学療法剤の活性を変化させるブチリルコリンエステラーゼ変異体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080213281A1 (enExample) |
| EP (1) | EP1581253A4 (enExample) |
| JP (1) | JP2006508665A (enExample) |
| CN (1) | CN100341568C (enExample) |
| AU (1) | AU2003298920A1 (enExample) |
| BR (1) | BR0316865A (enExample) |
| CA (1) | CA2507626A1 (enExample) |
| MX (1) | MXPA05005996A (enExample) |
| WO (1) | WO2004050041A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989261B2 (en) * | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| EP2049661A4 (en) * | 2006-08-04 | 2012-07-04 | Pharmathene Inc | RECOMBINANT BUTYRYLCHOLINESTERASE WITH LONG HALF-LIFE |
| US20100008978A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Nanoparticles effective for internalization into cells |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| KR20110008075A (ko) * | 2008-05-16 | 2011-01-25 | 넥타르 테라퓨틱스 | 콜린에스테라아제 부분 및 폴리머의 콘쥬게이트 |
| WO2011084145A2 (en) * | 2009-12-21 | 2011-07-14 | Pharmathene, Inc. | Recombinant butyrylcholinesterases and truncates thereof |
| CN103898101B (zh) * | 2012-12-27 | 2017-08-08 | 上海桀蒙生物技术有限公司 | 利用转基因动物乳腺生物平台大规模生产重组人丁酰胆碱酯酶的方法 |
| CN104630177A (zh) * | 2013-11-08 | 2015-05-20 | 中国农业大学 | 一种利用人丁酰胆碱酯酶迷你基因在乳腺中表达重组人丁酰胆碱脂酶的方法 |
| EP3137098A4 (en) | 2014-04-29 | 2017-11-01 | Mayo Foundation for Medical Education and Research | Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin |
| WO2018053216A1 (en) * | 2016-09-15 | 2018-03-22 | Mayo Foundation For Medical Education And Research | Methods and materials for using butyrylcholinesterases to treat cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0633318A1 (en) * | 1987-09-11 | 1995-01-11 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5264563A (en) * | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
| US5506125A (en) * | 1993-12-22 | 1996-04-09 | Agracetus, Inc. | Gene delivery instrument with replaceable cartridges |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US6001625A (en) * | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
| EP1088104B1 (en) * | 1998-06-16 | 2006-02-08 | Nova Molecular, Inc. | Methods for treating a neurological disease by determining bche genotype |
| CN1331339A (zh) * | 2000-06-26 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人dna拓扑异构酶i11.44和编码这种多肽的多核苷酸 |
| US20030153062A1 (en) * | 2001-12-20 | 2003-08-14 | Watkins Jeffry D. | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| CA2433057A1 (en) * | 2000-12-26 | 2002-08-22 | Applied Molecular Evolution, Inc. | Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use |
| US7070973B2 (en) * | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
| US7049121B2 (en) * | 2001-12-20 | 2006-05-23 | Applied Molecular Evolution | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US6989261B2 (en) * | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
-
2003
- 2003-12-04 EP EP03796682A patent/EP1581253A4/en not_active Withdrawn
- 2003-12-04 US US10/535,441 patent/US20080213281A1/en not_active Abandoned
- 2003-12-04 WO PCT/US2003/038684 patent/WO2004050041A2/en not_active Ceased
- 2003-12-04 MX MXPA05005996A patent/MXPA05005996A/es not_active Application Discontinuation
- 2003-12-04 CN CNB2003801050807A patent/CN100341568C/zh not_active Expired - Fee Related
- 2003-12-04 CA CA002507626A patent/CA2507626A1/en not_active Abandoned
- 2003-12-04 AU AU2003298920A patent/AU2003298920A1/en not_active Abandoned
- 2003-12-04 JP JP2004557611A patent/JP2006508665A/ja active Pending
- 2003-12-04 BR BR0316865-4A patent/BR0316865A/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Safari et al. | CRISPR Cpf1 proteins: structure, function and implications for genome editing | |
| KR102761827B1 (ko) | 타입 vi-b crispr 효소 및 시스템 | |
| Narayanavari et al. | Sleeping Beauty transposition: from biology to applications | |
| CN106103699B (zh) | 体细胞单倍体人类细胞系 | |
| Xue et al. | Improved bioethanol production using CRISPR/Cas9 to disrupt the ADH2 gene in Saccharomyces cerevisiae | |
| JP2006508665A5 (enExample) | ||
| JPH07502898A (ja) | 酵素ｒｎａ分子 | |
| JP2002535994A5 (enExample) | ||
| CN103911376A (zh) | CRISPR-Cas9靶向敲除乙肝病毒cccDNA及其特异性sgRNA | |
| CA2963820A1 (en) | Methods for improving crispr/cas-mediated genome-editing | |
| JP2009542228A5 (enExample) | ||
| CN107513538A (zh) | 基因敲除方法 | |
| AU2002304258A1 (en) | Method for the stable inversion of dna sequence by site-specific recombination and dna vectors and transgenic cells thereof | |
| WO2023102329A2 (en) | Effector proteins and uses thereof | |
| WO2023092132A1 (en) | Effector proteins and uses thereof | |
| US20230332218A1 (en) | Casy programmable nucleases and rna component systems | |
| CN107686842A (zh) | 一种靶多核苷酸编辑方法及其应用 | |
| JP7769691B2 (ja) | 新規の改良された塩基編集または編集用融合タンパク質およびその用途 | |
| US20240110163A1 (en) | Crispr-associated based-editing of the complementary strand | |
| Wang et al. | Cre‐mediated transgene integration in Chinese hamster ovary cells using minicircle DNA vectors | |
| US20230295666A1 (en) | Super-enchancers for recombinant gene expression in cho cells | |
| CN115896149A (zh) | 运动发酵单胞菌基因编辑质粒、试剂盒、方法及应用 | |
| WO2022241032A1 (en) | Enhanced guide nucleic acids and methods of use | |
| CN119372234A (zh) | 一种基于脱硫弧菌i-c型crispr基因编辑系统及其应用 | |
| CN114480348B (zh) | 一种融合蛋白及含有其的由双脱氨酶介导的碱基编辑系统和应用 |